Mode
Text Size
Log in / Sign up

Hyperbaric oxygen therapy associated with improved sleep quality in retrospective cohort studyHyperbaric oxygen therapy linked to improved sleep quality in retrospective study

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider HBOT-sleep association as preliminary; controlled trials needed for causality.

A retrospective longitudinal cohort study evaluated the effect of hyperbaric oxygen therapy (HBOT) on sleep quality in 395 patients at the Sagol Center. Participants included 180 healthy aging patients, 92 long COVID patients, and 123 PTSD patients. All received 60 HBOT sessions (2.0 ATA, 100% oxygen, 90 minutes, 5 days/week). No comparator group was reported.

The primary outcome was change in Pittsburgh Sleep Quality Index (PSQI) total score. Results showed PSQI total scores improved significantly in all three patient groups (p<0.001). Secondary outcomes included PSQI component scores, but specific effect sizes and absolute numerical changes were not reported. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported.

Key limitations include the retrospective design and absence of a control group, which prevents establishing causality. Funding sources and conflicts of interest were not reported. The study's practice relevance is limited by its observational nature and lack of control data. These findings indicate an association between HBOT and improved sleep quality that should be interpreted cautiously pending randomized controlled trials.

Researchers looked back at medical records to see if hyperbaric oxygen therapy (HBOT) might affect sleep quality. They studied 395 patients who had already completed 60 HBOT sessions for different reasons: 180 for healthy aging, 92 for long COVID, and 123 for PTSD. All patients had their sleep quality measured using a standard questionnaire before and after their treatment course.

The main finding was that sleep quality scores improved significantly in all three groups of patients after completing the HBOT sessions. The improvement was statistically strong, but the study did not report exactly how much better sleep became for the average person. The research did not mention any specific safety concerns or side effects related to the therapy in this group.

It is important to be careful with these results for two main reasons. First, this was a retrospective study, meaning researchers looked at past records rather than planning the study in advance. Second, there was no control group of similar patients who did not receive HBOT for comparison. Without a control group, we cannot know if the sleep improvement was truly due to the therapy or other factors.

Readers should understand this study shows an interesting link between HBOT and better sleep reports in these specific patient groups. The findings suggest this connection deserves further study in more carefully designed research. This single study does not prove HBOT is an effective sleep treatment, and people should not start this therapy solely for sleep problems based on this evidence.

What this means for you:
Early study links hyperbaric oxygen therapy to better sleep scores, but more research is needed to confirm the connection.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
BackgroundSleep disturbances are common in aging, post-traumatic stress disorder (PTSD), and long COVID, often linked to neuroinflammation, autonomic dysregulation, and neurodegeneration. Hyperbaric oxygen therapy (HBOT) promotes neuroplasticity through the hyperoxic-hypoxic paradox, improving cerebral perfusion, mitochondrial function, and reducing inflammation. While HBOT benefits sleep in certain conditions, its general effects across clinical populations remain unclear.MethodsThis retrospective longitudinal study evaluated Pittsburgh Sleep Quality Index (PSQI) changes in patients undergoing 60 HBOT sessions (2.0 ATA, 100% oxygen, 90 min, 5 days/week) at the Sagol Center. Participants included individuals treated for healthy aging (n = 180), long COVID (n = 92), or PTSD (n = 123). Pre- and post-treatment PSQI total and component scores were compared using paired t-tests and Wilcoxon signed-rank test was used for PSQI components. Regression analysis identified predictors of improvement.ResultsAmong 395 patients (mean age at baseline 57.9 ± 14.6 years, 31% female), baseline PSQI scores were highest in PTSD. Post-HBOT, total PSQI scores improved significantly in all groups (p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.